A Phase I/II Study of GMX1777 in Combination With Temozolomide for the Treatment of Metastatic Melanoma

NCT00724841 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

1

Enrollment

INDUSTRY

Sponsor class

Stopped Study terminated prematurely due to financial contraints.

Conditions

Metastatic Melanoma

Interventions

DRUG: Obatoclax Mesylate
DRUG: Temozolomide

Sponsor

Gemin X